Per this article from mid-2018 it was on pace for
Post# of 154090
(Total Views: 829)
Posted On: 05/08/2019 11:55:00 PM
Per this article from mid-2018 it was on pace for $638M in 2018 (only Pfizer’s share of the revenue) and could be $1B if an earlier indication is approved.
If Pfizer owned Xtandi outright, it would certainly come out ahead on its Medivation deal, but it has to share those sales with Astellas. The Japanese pharma cuts Pfizer a tiered royalty on international sales, and the partners share U.S. profits. Despite having to share, Pfizer's on pace to record around $638 million in Xtandi-related revenue this year. If the FDA green-lights an earlier indication for the drug, it could begin contributing around $1 billion annually in high-margin revenue within a few years.
https://www.fool.com/amp/investing/2018/06/12...cceed.aspx
If Pfizer owned Xtandi outright, it would certainly come out ahead on its Medivation deal, but it has to share those sales with Astellas. The Japanese pharma cuts Pfizer a tiered royalty on international sales, and the partners share U.S. profits. Despite having to share, Pfizer's on pace to record around $638 million in Xtandi-related revenue this year. If the FDA green-lights an earlier indication for the drug, it could begin contributing around $1 billion annually in high-margin revenue within a few years.
https://www.fool.com/amp/investing/2018/06/12...cceed.aspx
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.